Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regional Coverage

Asia Pacific

Set Alert for Asia Pacific

Latest From Asia Pacific

Kolmar Korea Eyes Pharma Expansion Via CJ HealthCare Acquisition

The acquisition of mid-size South Korean pharma firm CJ HealthCare is set to boost Kolmar Korea's pharma business, enabling the cosmetics and pharma company to transform into a larger and more integrated healthcare firm.

Commercial Deals

Momentum At Indian Innovation Start-Ups: Will Pharma Take Notice?

Several Indian startups - many with overseas links - appear to be taking a shot at developing, among others, novel treatments targeting multi-drug resistant infections, biobetters and personalized cell based therapy. Funding, though, hasn’t been easy, according to one biopharma advisory firm.

Commercial Companies

Osteoarthritis Stem Cell Therapy Could Be On Sale In India By 2020

A novel Indian stem cell injection treatment intended to slow down joint damage caused by osteoarthritis and potentially avert replacement surgery will undergo domestic Phase III trials this year and could be on sale in the country by 2020 under a licensing deal between Alkem Laboratories and biotech firm Stempeutics.

Commercial Deals

Lilly Halts Hanmi BTK Inhibitor Trial For RA, Mulls Other Indications

Hanmi Pharmaceutical shares fell sharply on the news Lilly has halted Phase II trials of the South  Korean firm’s BTK inhibitor for rheumatoid arthritis. But Hanmi says its license contract remains intact and that the two firms are discussing the potential development of the molecule for other indications.

Research & Development South Korea

Can Sanofi’s Toujeo Prickle Tresiba In India?

Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.

India Pricing Strategies

Arix And China's Fosun Ink A Strategic Partnership

A new strategic partnership has been forged between Arix Bioscience and China's Fosun International to develop new business opportunities in China.

Deals StartUps and SMEs
See All

Europe

Set Alert for Europe

Latest From Europe

Richter Expects Esmya Sales To Drop 50% Following EU Restrictions Over Liver Concerns

Restrictions placed on the use of Gedeon Richter’s uterine fibroid drug Esmya by the European Medicines Agency could significantly dent the product’s sales in the EU, and could also have a knock-on effect in the US, where the FDA accepted an NDA filing for the drug in October 2017.

Drug Safety Drug Review

J&J Opens First JLABS Site In Europe

Johnson & Johnson Innovation has opened its first JLABS incubator in Europe, the 10th worldwide, with close links to its pharma R&D unit Janssen.

Belgium StartUps and SMEs

Quality UK Biotechs Will Dodge Post-Brexit VC Drought

With the UK deadline to leave the European Union just over 12 months away, UK companies will see access to European Investment Fund-backed venture capital restricted. Quality companies, however, should not be fearful.

Commercial Companies

Opdivo’s EU Colorectal Cancer Setback ‘More Than Offset’ By Potential Gains In Combination

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Advisory Committees Drug Review

Puma's Likely Neratinib EU Knockback May Be Temporary

A positive opinion on the marketing application for Puma's neratinib in the EU is unlikely next month after a recent discussion with regulators failed to satisfy risk-benefit concerns, but more data on controlling diarrhea are expected shortly.

Approvals Cancer

Amgen Wins First EU Avastin Biosimilar Approval, But When Will It Launch?

Partners Amgen and Allergan have become the first biosimilar developers to win EU approval for a copycat version of Roche's Avastin; commercialization preparation is underway but predicting a launch date for the product is more complicated.

EU Approvals
See All

United States

Set Alert for United States

Latest From United States

Prime Therapeutics Expanding Formulary Exclusion Program In 2018

The NetResults formulary contributed to a 0.2% decline in overall drug spending by the pharmacy benefit manager's commercial clients in 2017, according to Prime Therapeutics' Drug Trend report.
Pharmacy Benefit Management Pricing Strategies

Richter Expects Esmya Sales To Drop 50% Following EU Restrictions Over Liver Concerns

Restrictions placed on the use of Gedeon Richter’s uterine fibroid drug Esmya by the European Medicines Agency could significantly dent the product’s sales in the EU, and could also have a knock-on effect in the US, where the FDA accepted an NDA filing for the drug in October 2017.

Drug Safety Drug Review

US FDA Advisory Cmte. Review Of Charleston's Hydexor Exposes Flaws In Commercial Strategy

Physicians may be hesitant to prescribe the opioid/anti-emetic combo for several reasons; panelists were concerned the company hasn't figured out a specific commercial audience for Hydexor at this point in the review process.
Advisory Committees Neurology

Mehta Analysis: How Buffett And Friends Can Succeed, And How Pharma Would Be Affected

How Warren Buffett's company Berkshire Hathaway, Amazon and JPMorgan will address the challenge of creating affordable, quality healthcare for their employees in the US is far from clear, but they are intent on trying. Viren Mehta, founding partner of Mehta Partners LLC, considers what approach they might take to succeed where others have failed, and how such a course would impact on the pharma sector.

Private Payers Healthcare Systems

Rolontis Leads Hanmi’s Global Ambitions As ADVANCE Phase III Endpoint Met

Rolontis, a novel, long-acting granulocyte colony-stimulating factor (G-CSF) licensed out to Spectrum Pharmaceuticals, has become Hanmi Pharmaceuticals' first drug developed with its proprietary platform to approach the regulatory filings stage in global markets.

Research & Development South Korea

Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress

Alongside a build-up in the US, Cipla is keeping a sharp eye on its “profitability profile” in this market and expects to rationalize products that don’t fit the bill. But it remains on track to establishing a respiratory franchise in key regulated markets, with generic Advair studies moving forward in the US.

Commercial Strategy
See All
UsernamePublicRestriction

Register